Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest sells future royalties on Furiex’s alogliptin, Priligy for $415mm

Executive Summary

Royalty Pharma acquired from Forest Laboratories Inc. the future royalties owed on the Type II diabetes product Nesina/Vipidia (alogliptin), and Priligy (dapoxetine), a premature ejaculation treatment. In return, Forest received $415mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies